Currently, there are five manufacturers of new coronavirus vaccines approved for conditional listing or emergency use. Among them, three inactivated vaccines and one adenovirus vector vaccine have been conditionally approved for marketing; in addition, one recombinant neocoronavirus vaccine (CHO cells) has been approved for emergency use. The five approved neo-coronavirus vaccines are administered to the deltoid muscle of the upper arm, and the route of administration is intramuscular injection. Currently, two doses of inactivated neo-coronavirus vaccine are required; the interval between the first and second doses should be 3 weeks or more, and the second dose should be completed as early as possible within 8 weeks after the first dose. Adenovirus vector vaccine: 1 dose is required. Recombinant subunit vaccine: 3 doses are required; the interval between the first and second doses and between the second and third doses is recommended to be 4 weeks and above. Try to complete the 2nd dose within 8 weeks after the first dose, and the 3rd dose within 6 months after the first dose. The second dose of New Crown vaccine has the same composition as the first dose, and it is still recommended to complete the vaccination with the same vaccine product at this stage. In case of special circumstances such as the vaccine cannot continue to be supplied or the recipient is vaccinated in a different place, i.e. the vaccination cannot be completed with the same vaccine product, the vaccination can be completed with vaccine products of other manufacturers of the same type. In specific immunization procedures, if a serious allergic reaction occurs with the first dose of vaccine and cannot be ruled out to be caused by the vaccine, a second dose of vaccination is not recommended. Therefore, it is recommended to know the vaccine components in advance and avoid vaccination if you have previous allergies to the vaccine components. At the time of vaccination, the vaccinees should also report their health status, disease history, and allergy history to the vaccinating doctor truthfully. Up to now, it is still necessary to receive the new crown vaccine. On the one hand, the majority of the population will be immune, thus effectively reducing the risk of morbidity, severe illness and death; on the other hand, through orderly vaccination against NCCV, an immune barrier can be gradually established in the population to interrupt the epidemic of NCC pneumonia.